• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Rates of Dissatisfaction High for Hidradenitis Suppurativa Care

Medically reviewed by Carmen Pope, BPharm. Last updated on April 7, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, April 7, 2025 -- The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to undertreatment with available therapies, according to study published in the April issue of the Journal of Drugs in Dermatology.

Andeulazia Murdock, from the George Washington School of Medicine and Health Sciences in Washington, D.C., and colleagues distributed a survey to examine perceptions of current and emerging HS treatments and their impact on quality of life among respondents aged 18 years and older. Overall, 423 participants completed the entire survey.

The researchers found that <20 percent of respondents (76/423) were satisfied or very satisfied with current treatment options. Only 39 and/or 26 percent of the 244 patients with self-reported disease severity of Hurley stage II or III were being treated with biologics and/or hormone therapy, respectively, indicating undertreatment per current guidelines. Seventy-four percent of the respondents were unaware of U.S. Food and Drug Administration-approved treatments; more than half (56 percent) reported that these options had not been discussed by their dermatologist or health care provider. Sixty percent of respondents felt it was important to have FDA-approved therapies, believing it would result in improved physical health, mental health, and/or personal relationships (86, 78, and 60 percent, respectively).

"Our goal with this study was to highlight the multifaceted positive impact of new FDA treatments on those living with hidradenitis and the importance of pharma investment in this space," coauthor Adam Friedman, M.D., also from the George Washington School of Medicine and Health Sciences, said in a statement. "We also found that there are still significant gaps in care and dissatisfaction with current treatment approaches."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.